Nine New Drugs Under Clinical Stage: Dr Reddy's
Dr Reddy's Laboratories has said it has nine new drugs in different areas, including metabolic disorders and cardiovascular disorders, Psoriasis and migraine, under clinical development stage.
According to a filing with US SEC, the drug maker said as of March 31, 2014, DRL had 20 active products in the proprietary products pipeline, of which nine were in clinical development stage.
"Since repositioning our research activities in the years ended March 31, 2009 and 2010, our proprietary products segment has focused its efforts towards developing drugs to meet key unmet clinical needs.
"We have built a pipeline of assets that we expect to produce a steady stream of investigational new drugs in the coming years...As of March 31, 2014, we had 20 active products in our proprietary products pipeline, of which 9 were in clinical development stage," Dr Reddy's stated.
The proprietary products segment focuses on building a pipeline in the therapeutic areas of neurology, pain management, dermatology and infectious diseases, DRL said.
It said the new drug research on metabolic disorders/cardiovascular disorders, atopic dermatitis/psoriasis and anti-infective is in phase-II while migraine and psoriasis ones are in phase-III. The remaining one is in phase-I stage.
"In addition to the above, we have three programs which are in pharmacokinetic, bioavailability and bioequivalence studies in the migraine and dermatology therapeutic areas," DRL said.
New drug phase-III can be described as larger scale clinical studies conducted in patients to provide sufficient data for statistical proof of efficacy and safety while in phase-II clinical studies are conducted with groups of patients to determine preliminary efficacy, dosage and expanded evidence of safety.
The clinical trial process can take 5 to 10 years or more to complete, and there can be no assurance that the data collected will be in compliance with good clinical practice regulations, will demonstrate that the product is safe or effective, or, in the case of a biologic product, pure and potent, or will provide sufficient data to support USFDA approval of the product, the drug maker explained.
"We may cumulatively invest in Biologics, approximately $150 million, and proprietary products approximately USD 300 million over next 3 to 4 years till these respective businesses become self-sufficient and cash accretive," the latest DRL investor presentation said.
The research and development expenses for FY 14 stood at Rs 1,240 crore, year-on-year increase of 62 per cent against Rs 767 crore in FY13.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.